Interruption study of viremia of patients with hemorrhagic fever with renal syndrome in the febrile phase.
Kinetic changes of viremia were observed in 287 cases of hemorrhagic fever with renal syndrome (HFRS) in whom ribavirin was administered with double blind random control studied by means of virus isolation, indirect immunofluorescence assay and enzyme-linked immunosorbent assay. The positive rate of viremia was 79.7% (Sp = 3%) and positive rate of HERS IgM was 85% (Sp = 3.1%) before treatment. Viremia could be interrupted by ribavirin as in the ribavirin treated group, the viremia positive rate decreased, duration of viremia was shortened, viral antigen products, virus titer and HFRS IgG antibody level were reduced as compared with the control group. This showed that viremia was very frequent in patients in the febrile phase and ribavirin is an effective antiviral drug in HFRS during the febrile phase. Dosage and course of treatment of this drug are discussed.
Virus Research Institute, Hubei Medical College, Wuhan.
Z Q
ZQ
Yang
T M
TM
Zhang
M V
MV
Zhang
Z M
ZM
Zheng
Z J
ZJ
Hu
C F
CF
Qu
J M
JM
Xiang
J W
JW
Huggins
T M
TM
Cosgriff
J I
JI
Smith
D004311:Double-Blind Method; D005334:Fever; D006480:Hemorrhagic Fever with Renal Syndrome / Q000188:drug therapy*; D006801:Humans; D012254:Ribavirin / Q000627:therapeutic use*; D014766:Viremia / Q000188:drug therapy*
D012254:Ribavirin